Meet Clay Siegall, the Man behind the Success of Seattle Genetics

For many years now, Seattle Genetics has been making steps towards becoming one of the biggest pharmaceutical companies in Seattle. However, the concern for most people is if it will attain its goals or will it end up being bought just like many others that had the same objective. The organization’s co-founder and the CEO, Clay Siegall notes that Seattle Genetics has all it takes to achieve its goals. Currently, it is the biggest biotech company in Washington, with more than 800 employees. It also has a high market value of almost $10 billion. By focusing on the production of antibody drugs to help in the fight against cancer, the company will be able to reach global markets.

Seattle Genetics has 11 drugs set aside to help it attain its goal. Adcetrics has already been approved by the FDA as a second line drug in the treatment of Hodgkin Lymphoma, which gives it more potential over the others. Some of the other drugs include 22ME, 33A, and LIV1 all of, which treat different cancers. The drugs can propel the company to its goal as they offer better alternatives to cancer treatments such as chemo. The company’s vast size favors it because most investors are confident with big companies since they can increase productivity, hence, more returns. Furthermore the company’s spending on research and also increased sales are proof that it is on its way to becoming a big Pharma.

About Clay Siegall

Siegall, a Ph.D. holder from George Washington University, is the brains behind the success of Seattle Genetics. The company was established in 1998, and he was one of the co-founders. Today, he serves as the chairman and the CEO. Clay plays a remarkable role in the commercialization of antibody based cancer drugs such as Adcetrics, which is now gaining global recognition.

Clay has worked with numerous major companies in the health industry such as National Cancer Institute and Bristol- Myer Pharmaceuticals. He is a director in other enterprises such as Ultragenyx and Alder Bio Pharmaceuticals. Siegall is an alumnus of the University of Maryland where he graduated with a B.S in Zoology. Siegall is also a renowned author.

Leave a Reply

Your email address will not be published. Required fields are marked *